MiMedx Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for MiMedx Group (MDXG).

Price Target Range — 9 Quarters

Analyst Consensus — 6 Analysts

1S.Buy

5Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$9Upside to Avg. PT+177.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$6→$8
Aug 17, 2026	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$8
Apr 30, 2026	Citizens	David Turkaly	PT Cut	Market Outperform	$7→$6
Apr 20, 2026	Citizens	David Turkaly	PT Cut	Market Outperform	$10→$7
Apr 17, 2026	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$10→$7
Feb 23, 2026	Citizens	David Turkaly	Initiate	Market Outperform	$10
Feb 17, 2026	Cantor Fitzgerald	Sarah James	PT Cut	Overweight	$12→$8
Jan 20, 2026	Lake Street	Brooks O'Neil	PT Cut	Buy	$12→$10
Dec 17, 2025	Mizuho	Anthony Petrone	PT Cut	Outperform	$12→$10
Jul 31, 2025	Cantor Fitzgerald	Ross Osborn	PT Raise	Overweight	$11→$12
Jul 15, 2025	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$11
Feb 27, 2025	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$13
Aug 1, 2024	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$11
Aug 1, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$14→$12
Jul 2, 2024	Cantor Fitzgerald	Ross Osborn	Initiate	Overweight	$11
May 1, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$11
Mar 7, 2024	Lake Street	Brooks O'Neil	Initiate	Buy	$12
Mar 1, 2024	Mizuho	Anthony Petrone	PT Raise	Buy	$13→$14

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8

Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target

Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $7

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and lowers the price target from $10 to $7.

Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on MiMedx Group, Lowers Price Target to $7

Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers the price target from $10 to $7.

Benzinga Newsdesk

Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock

Benzinga Insights

MiMedx Group Inc

MiMedx Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8

PRO
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target

PRO
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6

PRO
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $7

PRO
Craig-Hallum Maintains Buy on MiMedx Group, Lowers Price Target to $7

Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock

People Also Watch

People Also Watch

MiMedx Group Inc

MiMedx Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCraig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8

PROCantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target

PROCitizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6

PROCitizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $7

PROCraig-Hallum Maintains Buy on MiMedx Group, Lowers Price Target to $7

Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock

People Also Watch

People Also Watch

PRO
Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8

PRO
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target

PRO
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6

PRO
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $7

PRO
Craig-Hallum Maintains Buy on MiMedx Group, Lowers Price Target to $7